信达生物开挂了!独家品种暴涨超900%,50款1类新药来势汹汹,6款新药上市可期

金融界
Aug 16, 2025

精彩内容日前,信达生物公布2025年半年报,报告期内总产品收入超52亿元,同比增长35%以上。今年以来,信达生物新药研发进展不断:拿下全球首个GCG/GLP-1双靶点药物及国内首个IGF-1R抗体;7款1类新药首次获批临床等。目前公司有52款新药(50款1类新药)在国内处于申请临床及以上阶段,涵盖小分子、单抗、双抗、ADC、CAR-T等药物形式,其中6款新药已处于NDA或III期临床阶段,上市可期...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10